Truemeds Raises $22mn In Series B Funding Round Led By Westbridge Capital

Telehealth Platform Truemeds, closed its series B funding round at $22 million led by private equity fund Westbridge Capital. The new funding round also saw participation from existing investors including InfoEdge Ventures, Asha Impact and IAN Fund. The round witnessed oversubscription from new and existing investors.

The company plans to utilise the funds to accelerate growth in the untapped domestic market and expand its coverage across the country.

Founded by Ex-Abbott executives, Akshat Nayyar and Dr. Kunal Wani, Truemeds has witnessed phenomenal growth in the last 2 years on the back of strong product-market fit and a massive organic demand.

Commenting on the announcement Akshat Nayyar, Co-founder & CEO of Truemeds said “India is one of the very few markets where we have pseudo-categorisation of medicines in branded and generic-generic to create different price tiers between them. 95 per cent of the drugs sold in India are off-patent (thus technically generics). There is absolutely no difference in the scientific composition of generics and branded drugs."

He further added" "Indian generic-generic market is growing at 1.5 times the overall pharmaceutical market and following the US landscape where the generics prescription share moved from 40 per cent in 2005 to over 85 per cent in 2019. The market move towards generics is inevitable and Truemeds will lead that change.”

At present, Truemeds have presence in Maharashtra and the company is currently fulfilling over 100,000 orders every month and growing rapidly. In an effort to improve the customer experience and reach, the company plans to triple its fulfilment centres across the country in the next 6 months.

Sandeep Singhal, Managing Director, Westbridge Capital commented, “We are excited to partner with Truemeds as they create value for patients by delivering high quality drugs at extremely affordable prices at the patients' doorstep. The founding team’s strong category understanding has resulted in the success at Truemeds and we are excited to help take the company to the next level.”

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor